2023
DOI: 10.3390/ijms24010892
|View full text |Cite
|
Sign up to set email alerts
|

Concentration-Dependent Efficacy of Recombinant Human Bone Morphogenetic Protein-2 Using a HA/β-TCP Hydrogel Carrier in a Mini-Pig Vertebral Oblique Lateral Interbody Fusion Model

Abstract: Bone morphogenetic protein-2 (BMP-2) is used in the treatment of degenerative spinal disease and vertebral fractures, spine fusion, dental surgery, and facial surgery. However, high doses are associated with side effects such as inflammation and osteophytes. In this study, we performed spinal fusion surgery on mini-pigs using BMP-2 and a HA/β-TCP hydrogel carrier, and evaluated the degree of fusion and osteophyte growth according to time and dosage. Increasing the dose of BMP-2 led to a significantly higher fu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 47 publications
(61 reference statements)
0
1
0
Order By: Relevance
“…PLGA nanoparticles are widely used bio-material candidate for drug delivery systems for its good biocompatibility and biodegradation properties as well as the controllable drug-releasing rate ( Ding and Zhu, 2018 ; Zhao et al, 2019 ). Growth factors like SDF-1 and BMP-2 are unstable and easily degraded, and require long-term and repeated administrations to maintain the effective concentration of growth factors in vivo ( Lee et al, 2023 ; Zhang et al, 2023 ). Moreover, intravenous administration of growth factors easily leads to their accumulation in untargeted organs (like liver and kidney), causing unnecessary toxicity and side effects.…”
Section: Discussionmentioning
confidence: 99%
“…PLGA nanoparticles are widely used bio-material candidate for drug delivery systems for its good biocompatibility and biodegradation properties as well as the controllable drug-releasing rate ( Ding and Zhu, 2018 ; Zhao et al, 2019 ). Growth factors like SDF-1 and BMP-2 are unstable and easily degraded, and require long-term and repeated administrations to maintain the effective concentration of growth factors in vivo ( Lee et al, 2023 ; Zhang et al, 2023 ). Moreover, intravenous administration of growth factors easily leads to their accumulation in untargeted organs (like liver and kidney), causing unnecessary toxicity and side effects.…”
Section: Discussionmentioning
confidence: 99%